0215196901
ICNA0215196901EA
548
EUR
InStock
ICNA0215196901
Epoprosterol sodium ≥99%, poudre blanche
Epoprosterol sodium
PGI2 is synthesized primarily in vascular endothelial cells. It is a potent inhibitor of platelet aggregation, relaxes vascular smooth muscle, and also increases cyclic AMP concentration in human platelets.
Prostacyclin therapy improves hemodynamics in pulmonary arterial hypertension.
Prostaglandin I2 sodium salt stimulates platelet adenylyl cyclase. Nitric oxide is also produced in vascular endothelium where it inhibits platelet aggregation, regulates inducible cyclooxygenase production, and may work synergistically with prostacyclin to attenuate the thrombotic process. Prostacyclin is vasoprotective, protecting arterial walls from injury-induced lesions and cytoprotective in the liver and gastrointestinal tract.
Solutions of PGI2 at physiologic pH and room temperature will have a half-life from 1 to 12 minutes depending on buffer concentration. Half-life under physiological conditions is 2 minutes.
Attention: Research Use Only (RUO). Store Desiccated.